Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01848756 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers
A Phase 1 study, sponsored by Esanex.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01848756 is a Phase 1 study that was terminated before completion, run by Esanex. The registered enrollment target is 15 participants.
The verdict
NCT01848756, a Phase 1 study, was terminated before completion, sponsored by Esanex.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
Hsp90 is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90
Interventions
- DRUG SNX-5422
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2013-04 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01848756
The ClinicalTrials.gov registry entry for NCT01848756 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Esanex, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SNX-5422 is the first listed.
NCT01848756 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01848756 about?
NCT01848756 is a clinical study titled "Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers". Hsp90 is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90
What is the current status of trial NCT01848756?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2013-04. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01848756?
The interventions under investigation include: SNX-5422 (DRUG).
Who is sponsoring clinical trial NCT01848756?
This trial is sponsored by Esanex, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.